<H1>Chapter DOI: 10.1208/aapsj070247<br/>Cited-By Count: 13</H1><table border="1" width="30%"><tr><td>Total References</td><td>21</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>19</td></tr><tr><td>BibStructured Count</td><td width="10%">16</td></tr><tr><td>BibUnstructured Count</td><td width="10%">5</td></tr><tr><td>DOI already available in SpringerLink</td><td>11</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:67&#8211;95.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.67>10.1146/annurev.pharmtox.40.1.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibBook</td><td>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.<Emphasis Type="Italic">Exposure-Response Relationships&#8212;Study Design, Data Analysis, and Regulatory Applications</Emphasis>. Rockville, MD: Food and Drug Administration, 2003.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1997;61:275&#8211;291.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(97)90160-0>10.1016/S0009-9236(97)90160-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibBook</td><td>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.<Emphasis Type="Italic">Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products</Emphasis>. Rockville, MD: Food and Drug Administration, 1999.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>The</span> <span style='background:#DDDDDD'>US</span></span></aug> Congress. The Federal Food, Drug, and Cosmetic Act, as amended in <span style='background:#66FF66'>1962</span>. Pub. L. No. 87-781, 76 Stat. <span style='background:#FFCC66'>780</span>. <span style='background:#D279FF'>1962</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>The US</span> <span style='background:#BCBCBC'>Congress</span></span></aug>. The Food and Drug Administration Modernization Act of <span style='background:#66FF66'>1997</span>. Pub. L. No. 105-115, 111 Stat. <span style='background:#66FF66'>2295</span>. 1997.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;73:481&#8211;490.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(03)00018-3>10.1016/S0009-9236(03)00018-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Dower SK, Smith CA, Park LS. Human cytokine receptors.<Emphasis Type="Italic">J Clin Immunol</Emphasis>. 1990;10:289&#8211;299.</td><td><a href=http://dx.doi.org/10.1007/BF00917473>10.1007/BF00917473</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.<Emphasis Type="Italic">J Rheumatol</Emphasis>. 2001;28:1238&#8211;1244.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2000;343:1586&#8211;1593.</td><td><a href=http://dx.doi.org/10.1056/NEJM200011303432201>10.1056/NEJM200011303432201</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Label for &lt;Superscript&gt;Enbrel&#174;&lt;/Superscript&gt; (etanercept)</span>. <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers.<Emphasis Type="Italic">Ann Pharmacother</Emphasis>. 2000;34:161&#8211;164.</td><td><a href=http://dx.doi.org/10.1345/aph.19126>10.1345/aph.19126</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Lebsack ME, Hanna RK, Lange MA. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers.<Emphasis Type="Italic">Pharmacotherapy</Emphasis>. 1997;17:1181&#8211;1189.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;73:348&#8211;365.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(02)17635-1>10.1016/S0009-9236(02)17635-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibUnstructured</td><td>Immunex. Data on File, Etanercept. <span style='background:#66FF66'>1999</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Bonate PL. Clinical trial simulation in drug development.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2000;17:252&#8211;256.</td><td><a href=http://dx.doi.org/10.1023/A:1007548719885>10.1023/A:1007548719885</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2000;68:568&#8211;577.</td><td><a href=http://dx.doi.org/10.1067/mcp.2000.110975>10.1067/mcp.2000.110975</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. 50 mg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 25 mg twice weekly dosing.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2002;71:90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.<Emphasis Type="Italic">Arthritis Rheum</Emphasis>. 2004;50:353&#8211;363.</td><td><a href=http://dx.doi.org/10.1002/art.20019>10.1002/art.20019</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2005;45:246&#8211;256.</td><td><a href=http://dx.doi.org/10.1177/0091270004271945>10.1177/0091270004271945</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Amgen.</span> FDA approves enbrel for once-weekly dosing: new dosing option offers convenience to patients while providing comparable efficacy and tolerability. Amgen press release. October 23, <span style='background:#66FF66'>2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>